Douglas A. Roeder

Douglas A. Roeder (board member) discloses dealings in 3 companies, chiefly Senseonics Holdings, Inc., Tandem Diabetes Care Inc and TriVascular Technologies, Inc. In total, 28 filings cover trades dated from 3 February 2016 to 1 October 2026.

In open-market terms, that means 6 purchases worth €572k on one side and 3 sales worth €621k on the other. Sales outweigh purchases by €49k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 13 share grants and 2 option exercises. 2026 to date brings 2 purchases and no sales.

Half of the purchases are above €98k and half below. Clusters matter here: 4 out of 6 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 50% of cases, with a median move of +3.0%. This is a record of the past, not a forecast.

The latest filing, published on 5 October 2026, reports a share grant of €13k in Senseonics Holdings, Inc. The clock since the last published purchase (20 August 2026) now reads 58 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.